期刊文献+

他汀类药物临床多效性研究进展 被引量:13

Research Progress in Clinical Pleiotropic Effects of Statins
下载PDF
导出
摘要 他汀类药物被认为是降低血清胆固醇水平最有效的药物。他汀类药物除脂质调节作用外的其他非脂质调节功能的多效性可使不同疾病的患者受益。现发现他汀类药物最重要的非脂质调节作用包括抗炎、抗氧化、抗栓、改善内皮功能、减轻血管重构、免疫调节及神经保护等。在上述生物学进程中,Rho/Rho相关卷曲蛋白激酶、Ras相关C3肉毒毒素底物、过氧化物酶体增殖物激活受体等信号通路可视为他汀类药物的多效性的主要分子生物学机制。 Statins have been viewed as the most effective drugs to reduce cholesterol serum level. Recent studies have demonstrated non-lipid modifiable pleiotropic effects of statins, which could benefit patients with different diseases. The most important non-lipid modifiable effects of statins include anti-inflammation, antioxidant, antithrombosis, improving endothelial dysfunction, attenuating vascular remodeling, immunomedulation, neuroprotection, etc. In particular, Ras homolog family members (Rho)/Rho associated coiled coil-containing protein kinases, Ras-related C3 botulinum toxin substrate and peroxi- some proliferator activated receptors signaling pathway can be regarded as the principle molecular mechanisms of the pleio- tropic effects of statins.
出处 《医学综述》 2017年第15期3056-3061,共6页 Medical Recapitulate
关键词 他汀类药物 临床多效性 非调脂作用 信号通路 Statins Clinical pleiotropic effects Non-lipid modifiable effects Signaling pathway
  • 相关文献

参考文献2

二级参考文献25

  • 1Chen Huang,Jianfeng Huang,Yu Tian,Xueli Yang,Dongfeng Gu.Sugar sweetened beverages consumption and risk of coronary heart disease: A meta-analysis of prospective studies[J]. Atherosclerosis . 2014 (1)
  • 2Clint L. Miller,Themistocles L. Assimes,Stephen B. Montgomery,Thomas Quertermous.Dissecting the Causal Genetic Mechanisms of Coronary Heart Disease[J]. Current Atherosclerosis Reports . 2014 (5)
  • 3Kirsten B. Holven,Ingunn Narverud,Henriette W. Lindvig,Bente Halvorsen,Gisle Langslet,Marit S. Nenseter,Stine M. Ulven,Leiv Ose,P?l Aukrust,Kjetil Retterst?l.Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatment[J]. Atherosclerosis . 2014
  • 4John D Abramson,Harriet G Rosenberg,Nicholas Jewell,James M Wright.Should people at low risk of cardiovascular disease take a statin?[J]. BMJ . 2013 (oct22 3)
  • 5Brian A. Ference,Wonsuk Yoo,Issa Alesh,Nitin Mahajan,Karolina K. Mirowska,Abhishek Mewada,Joel Kahn,Luis Afonso,Kim Allan Williams,John M. Flack.Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease[J]. Journal of the American College of Cardiology . 2012 (25)
  • 6Kevin E. Kip,Kim Hollabaugh,Oscar C. Marroquin,David O. Williams.The Problem With Composite End Points in Cardiovascular Studies[J]. Journal of the American College of Cardiology . 2008 (7)
  • 7MarieMiossec,PierreMiossec.New regulatory rules for clinical trials in the United States and the European Union: Key points and comparisons[J]. Arthritis & Rheumatism . 2006 (12)
  • 8Yadon Arad,Louise A. Spadaro,Marguerite Roth,David Newstein,Alan D. Guerci.Treatment of Asymptomatic Adults With Elevated Coronary Calcium Scores With Atorvastatin, Vitamin C, and Vitamin E[J]. Journal of the American College of Cardiology . 2005 (1)
  • 9Helen M Colhoun,D John Betteridge,Paul N Durrington,Graham A Hitman,H Andrew W Neil,Shona J Livingstone,Margaret J Thomason,Michael I Mackness,Valentine Charlton-Menys,John H Fuller.Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial[J]. The Lancet . 2004 (9435)
  • 10James H O’Keefe,Loren Cordain,William H Harris,Richard M Moe,Robert Vogel.Optimal low-density lipoprotein is 50 to 70 mg/dl[J]. Journal of the American College of Cardiology . 2004 (11)

共引文献56

同被引文献155

引证文献13

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部